首页> 外文OA文献 >Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin

【2h】

Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin

机译：生物标志物的意义预测预后和选择晚期胃癌患者的连续输注5-FU和5-FU和顺铂的组合中的治疗晚期胃癌患者的化疗方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Narikazu Boku; Atsushi Ohtsu; Shigeaki Yoshida; Kuniaki Shirao; Yasuhiro Shimada; Ichinosuke Hyodo; Hiroshi Saito; Yoshinori Miyata;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. [J] . Boku N, Ohtsu A, Yoshida S, Japanese journal of clinical oncology. . 2007,第4期

机译：生物标志物在连续输注5-FU与5-FU和顺铂联用之间预测晚期胃癌患者预后和选择化疗方案的意义。
2. Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin [J] . Narikazu Boku1 Atsushi Ohtsu2 Shigeaki Yoshida1 Kuniaki Shirao3 Yasuhiro Shimada3 Ichinosuke Hyodo4 Hiroshi Saito5 Yoshinori Miyata6 and Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group (GIOSG/JCOG) Japanese Journal of Clinical Oncology . 2007,第4期

机译：连续输注5-FU与5-FU和顺铂联用之间的生物学指标对晚期胃癌患者预后和化疗方案选择的意义
3. 3501 ORAL Capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC): a randomised phase III trial [J] . Y.Kang, W.Kang, D.Shin, European Journal of Cancer Supplements . 2007,第4期

机译：3501口服卡培他滨/顺铂与5-FU /顺铂连续输注作为晚期胃癌（AGC）患者（pts）的一线治疗：一项随机III期试验
4. Combination Chemotherapy with Intra-peritoneal Infusion of CDDP and S-l for Gastric Cancer with Peritoneal Metastasis or Positive Peritoneal Cytology [C] . H Fujiwara, A. Takagane, K. Abe, International Gastric Cancer Congress . 2005

机译：具有腹膜内输注CDDP和S-L的组合化疗，用于胃癌腹膜转移或阳性腹膜细胞学
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel cisplatin 5-FU (TCF) with epirubicin cisplatin 5-FU (ECF) [O] . Sanambar Sadighi, Mohammad Ali Mohagheghi, Ali Montazeri, 2006

机译：晚期胃癌患者的生活质量：比较多西他赛顺铂5-FU（TCF）与表柔比星顺铂5-FU（ECF）的随机试验
7. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin [O] . 朴成和, ボクナリカズ 2008

机译：生物标志物对5-FU连续输注与5-FU联合顺铂联合化疗对晚期胃癌患者预后及化疗方案选择的意义

Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin

著录项

引文网络

相似文献

相关主题

期刊订阅